Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Nachman

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
AIDS Research and Human Retroviruses|November 16, 2011
Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failureIngrid A Beck, Minyoung Jang, Jennifer McKernan-Mullin, et al.
Journal of Clinical Pharmacology|March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2010
Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected childrenAdriana Weinberg, Lin-Ye Song, Robert Walker, et al.
British Journal of Clinical Pharmacology|June 29, 2018
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in childrenElin M Svensson, Jeannine du Bois, Rene Kitshoff, et al.
The Lancet. HIV|April 16, 2023
Long-acting antiretrovirals and HIV treatment adherenceJean B Nachega, Kimberly K Scarsi, Monica Gandhi, et al.
JAMA Pediatrics|January 13, 2015
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazidM Elsa Villarino, Nigel A Scott, Stephen E Weis, et al.
The Pediatric Infectious Disease Journal|February 21, 2018
High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy TrialLisa M Cranmer, Heather R Draper, Anna M Mandalakas, et al.
Journal of the Pediatric Infectious Diseases Society|June 3, 2017
Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical TrialMolly A O'Gorman, Marian G Michaels, Sheldon L Kaplan, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
AIDS Research and Human Retroviruses|November 16, 2011
Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failureIngrid A Beck, Minyoung Jang, Jennifer McKernan-Mullin, et al.
Journal of Clinical Pharmacology|March 11, 2015
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of ageMatthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2010
Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected childrenAdriana Weinberg, Lin-Ye Song, Robert Walker, et al.
British Journal of Clinical Pharmacology|June 29, 2018
Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in childrenElin M Svensson, Jeannine du Bois, Rene Kitshoff, et al.
The Lancet. HIV|April 16, 2023
Long-acting antiretrovirals and HIV treatment adherenceJean B Nachega, Kimberly K Scarsi, Monica Gandhi, et al.
JAMA Pediatrics|January 13, 2015
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazidM Elsa Villarino, Nigel A Scott, Stephen E Weis, et al.
The Pediatric Infectious Disease Journal|February 21, 2018
High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy TrialLisa M Cranmer, Heather R Draper, Anna M Mandalakas, et al.
Journal of the Pediatric Infectious Diseases Society|June 3, 2017
Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical TrialMolly A O'Gorman, Marian G Michaels, Sheldon L Kaplan, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
Pageof 11